Developing a vaccine to enhance T-cell support for HIV antibody production
Official title: Optimal T-cell support for HIV neutralizing antibody induction to fusion peptide-inclusive regimens (Opti-FliP)
Funded at University of California at Davis · NIH-11062306 · Data updated 2026-11-12
This study is testing a new HIV vaccine designed to boost your immune system's ability to fight the virus, especially for those already living with HIV, by helping your body produce stronger antibodies and T-cells.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | December 17, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $3,552,620 |
| NIH project number | 1P01AI181044-01A1 |
| Project ID | NIH-11062306 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living with HIV, particularly those infected with clade C strains of the virus.
✕Less likely to help
Patients who are not infected with HIV or those who have advanced stages of AIDS may not benefit from this research.
What this research studies
This research focuses on creating an innovative HIV vaccine that enhances the body's immune response by promoting interactions between specific antibodies and T-cells. The approach involves using advanced vaccine techniques and adjuvants to stimulate high-quality T-cell responses that support the production of broadly neutralizing antibodies against HIV. By investigating how these immune components work together, the research aims to improve the effectiveness of HIV vaccines, particularly in individuals already infected with the virus. The study will include human participants to assess the immune responses generated by the vaccine regimen.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that significantly improves immune protection against the virus.
How similar studies have gone: Previous research has shown promise in using innovative vaccine strategies to elicit strong immune responses, suggesting potential for success in this approach.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Hartigan-O'connor, Dennis J. — University of California at Davis
- Study coordinator: Hartigan-O'connor, Dennis J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.